Evidence map›Paper›PMID 35966513›Full record

ArticleFrontiers in cardiovascular medicine2022

Novel Early Pregnancy Multimarker Screening Test for Preeclampsia Risk Prediction.

Kaspar Ratnik, Kristiina Rull, Oliver Aasmets, Triin Kikas, Ele Hanson, Kalle Kisand, Krista Fischer, Maris Laan

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. First Trimester Placental Biomarkers for Pregnancy Outcomes.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kaspar RatnikDepartment of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Kristiina RullDepartment of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Oliver AasmetsEstonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.
Triin KikasDepartment of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Ele HansonWomen's Clinic, Tartu University Hospital, Tartu, Estonia.
Kalle KisandDepartment of Internal Medicine, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
Krista FischerEstonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.
Maris LaanDepartment of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
University of Tartu · EETartu University Hospital · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preeclampsia (PE) is a common pregnancy-linked disease, causing preterm births, complicated deliveries, and health consequences for mothers and offspring. We have previously developed 6PLEX, a multiplex assay that measures PE-related maternal serum biomarkers ADAM12, sENG, leptin, PlGF, sFlt-1, and PTX3 in a single test tube. This study investigated the potential of 6PLEX to develop novel PE prediction models for early pregnancy. We analyzed 132 serum samples drawn at 70-275 gestational days (g days) from 53 pregnant women (PE,

Indexed as

6PLEXbiomarkersearly pregnancymultiplex immunoassayPreeclampsiaPTX3risk predictionstatistical modeling

Identifiers

PMID35966513
PMCPMC9363612
OpenAlexW4288033975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.